Global stock

NASDAQUSD

IDEXX Laboratories

IDXX

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

53/ 100

Overall score·IDXX

Current price

561.07USD

27/10/2026

P/E, P/B

Valuation

Weak

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Valuační násobky IDEXX jsou vysoké: P/E 36,5, PEG 2,83 a EV/EBITDA 25,7 ukazují na prémiové ocenění, což snižuje skóre hodnoty. Silnou stránkou je ziskovost a růst EPS, zatímco cena pod 50denním i 200denním průměrem, vyšší beta a omezená likvidita ukazují na slabší momentum a smíšenou stabilitu.

§ Outlook vs S&P 500Next 12 months

About the same

Estimated chance of beating the index: about 46%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Metrics summary

A quick look at IDEXX Laboratories (IDXX) combining financial health, the short-term signal, valuation, DCF, management quality and operating metrics. It is analytical context, not a recommendation to buy or sell.

53/100

The overall score is based mainly on long-term fundamentals, complemented by the current signal and the available qualitative rating of the company.

52/100

Neutral signal based on current news, price action and the economy.

24/100

A lower score means the stock is expensive relative to the company's earnings and assets.

166% above fair value

An estimate of what the stock should be worth based on the company's future cash.

+10%

How fast the company's revenue grows year on year.

90/100

How much the company earns from each unit of revenue and from invested capital.

43/100

Debt level, share-price volatility and how resilient the company is in bad times.

68/100

AI estimate of management quality, execution and capital allocation.

86/100

AI estimate of the company's durable competitive advantage.

§ Financial results

Financial results·IDXX

M USD

RevenueEBITDANet incomeEBITDA margin

Margins and profitability·IDXX

Net marginEBITDA marginDashed = estimate

Net margin

+24.6 %

FY 2025 · reported

EBITDA margin

+35.0 %

FY 2026 · estimate

Net margin

+25.0 %

last 12 months

Operating margin

+35.0 %

last 12 months

ROE

+74.2 %

last 12 months

FY = fiscal year · TTM = trailing 12 months

§ Context and events

Management

Jonathan J. Mazelsky je Executive Chairman. Andrew Emerson zastává funkci výkonného viceprezidenta, finančního ředitele a pokladníka; Michael J. Lane vede globální referenční laboratoře, diagnostická řešení a IT a Martin Smith odpovídá za globální provoz a výzkum a vývoj. Strategie společnosti stojí na rozvoji veterinární diagnostiky, laboratorních služeb a souvisejících informačních řešení.

Articles about IDEXX Laboratories, in Czech (0)

No articles yet. New analyses are published daily.

§ Upcoming results

2 November 2026

in 6 days

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is IDEXX Laboratories (IDXX)?

IDEXX Laboratories (IDXX) is a global stock traded on NASDAQ. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the IDEXX Laboratories price today?

As of 27 October 2026, IDEXX Laboratories trades at about 561.07 USD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy IDEXX Laboratories?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does IDEXX Laboratories pay a dividend?

IDEXX Laboratories either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is IDEXX Laboratories a good investment in 2026?

Our AI signal currently rates IDEXX Laboratories as neutral (score 52/100). Financial health comes out at 53/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. The DCF model currently puts the price about 166 % above its model fair value. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy IDEXX Laboratories

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Neutral

Earnings in 6 days

On 2 November 2026 the company publishes its quarterly results. This period tends to bring large price moves.

News summary

Fresh news

Signal 27/10, 19:02

UBS snížil cílovou cenu IDEXX z 670 na 627 USD; výsledky očekávané 2. listopadu mohou výhled podpořit, pokud překonají odhady růstu zisku a tržeb.

Růst ceny za 30 dní, vzestupný trend a RSI 63 mírně podporují krátkodobý výhled. Nižší cílová cena UBS a drobné snížení konsenzu EPS jej brzdí; diagnostický a veterinární segment nabízí strukturální oporu.

Risks: Slabší než očekávané výsledky nebo opatrný výhled vedení by mohly zvrátit cenové momentum a oslabit střednědobý růst.

More about the signal

Risks: Slabší než očekávané výsledky nebo opatrný výhled vedení by mohly zvrátit cenové momentum a oslabit střednědobý růst.

Signal history· 2

24/1017:0161 · Slightly positive
Před výsledky za 3. čtvrtletí se IDEXX podle zprávy dostává do pozornosti investorů; potvrzení růstu výsledky by podpořilo výhled, zklamání by jej oslabilo.
23/1005:0163 · Slightly positive
Zprávy zmiňují růst IDEXX po podpoře Jefferies a otázku dalšího růstu zisků díky vyššímu výhledu a rozšíření produktů; dopad podpoří potvrzení růstu výsledky.

The full 90-day signal history is part of Premium.

Ask the AI

§ Model fair value (DCF)

Overvalued166% above fair value

210.75

range 172.2 – 262.5

Current price

561.07 USD

27 Oct 26

PriceFair value range (DCF)UndervaluedOvervalued

What the calculation is based on

Model

210.75 USD

range 172.2 USD – 262.5 USD

: 8.0%
: 10.5%
: 13.09 USD

Předpokládaný růst 8 % ročně zohledňuje růst tržeb a EPS, ale zůstává konzervativní vzhledem k již zavedenému podnikání. Diskontní sazba 10,5 % odráží nadprůměrnou betu a terminální růst 2,5 % odpovídá dlouhodobému ekonomickému růstu.

DCF terms explained+

DCF (discounted cash flow) estimates how much cash the company will generate in the future and converts it into today's value per share.

Free cash flow (FCF) is the money left after running the business and investing. “12 m” means the last 12 months.

The discount rate expresses risk: the riskier the company, the higher the rate and the lower the fair value.

Fair value is a model estimate — not the market price and not an investment recommendation.

With Premium you can adjust growth, the discount rate and free cash flow, and the fair value recalculates live.

Adjust assumptions14 days free →

A model estimate, not an investment recommendation. Past performance does not guarantee future results.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 18 of 18

Valuation score

2/ 6

6/6 tests available

1. Below DCF fair value

166.2% above the DCF midpoint.

2. Well below DCF value

Discount = below the range or at least 15% below the midpoint.

3. Price vs. the last year

26% above the 1-year low (504.7 USD to 724.8 USD), based on stored daily prices.

4. P/E vs. similar companies

P/E 36.5 vs. median 26.4 (71 companies).

5. P/E relative to growth

PEG 2.8; a lower value means cheaper growth.

6. Analyst price target

25.0% vs. the current price, 12 analysts.

Price vs DCF

Current price

561.1 USD

Low 172.2 USDHigh 262.5 USD

Current priceDCF midpoint: 210.8 USD

Price vs analyst target

Current price

561.1 USD

Low 470.0 USDHigh 805.0 USD

Current priceAverage: 701.3 USD

DCF gap

above range

166.2% above the DCF midpoint (210.8 USD).

Analyst target

+25.0%

Average target 701.3 USD vs. price 561.1 USD.

Analyst consensus

Target range

470.0 USD - 805.0 USD

Coverage

12 analysts

Analyst consensus

2.2 / 5

Changes 180 d

+0 / -0

EPS next year

12.9%

Revenue next year

8.9%

Valuation multiples

36.5

25.4

9.0

25.7

2.8

52-week range26% above the low

504.7 USD724.8 USD

18.0%

10.0%

25.0%

74.2%

Price vs 50D4.0%

Price vs 200D-3.8%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 27/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

good

Vedení získává body za pokračující růst a rozšiřování diagnostického portfolia, skóre však snižují zvýšené governance riziko a slabší hodnocení představenstva a práv akcionářů.

strong

IDEXX těží ze zavedené značky, široké nabídky diagnostiky, referenčních laboratoří a propojeného softwaru, které podporují opakované využívání a náklady na změnu dodavatele.

Information

Type: Global stock
Symbol: IDXX
Exchange: NASDAQ
Currency: USD
Sector: Healthcare
: 36.5x
: 40.9B USD
: 68.0 %
: 1.55

§ Risk profile

Rizika zahrnují vysoké ocenění akcie, zpomalení výdajů na veterinární péči a tlak na marže či konkurenci v diagnostice. Českému investorovi navíc kolísání dolaru vůči koruně může zvýšit nebo snížit korunový výnos.

Ask the AI about IDEXX Laboratories All signals